Streetbeat News

Price Targets

SIBN

Cantor Fitzgerald analyst Ross Osborn has maintained an Overweight rating on SI-BONE (NASDAQ:SIBN) but lowered the price target from $30 to $25.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 4:32 pm

PAY

Wedbush analyst Moshe Katri maintains a Neutral rating on Paymentus Holdings (NYSE:PAY) and raises the price target from $11 to $16.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 4:28 pm

COIN

Wedbush analyst Moshe Katri has reiterated an Outperform rating on Coinbase Global (NASDAQ:COIN) and maintained a price target of $110.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 4:20 pm

CELH

Wedbush analyst Gerald Pascarelli has reiterated an Outperform rating on Celsius Holdings (NASDAQ:CELH) and maintained a price target of $225.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 4:14 pm

CVCO

Wedbush analyst Jay McCanless has maintained an 'Outperform' rating on Cavco Industries (NASDAQ:CVCO) but lowered the price target from $390 to $380.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 4:11 pm

LULU

In the last quarter, Lululemon Athletica (NASDAQ:LULU) received 5 bullish, 12 somewhat bullish, and 2 indifferent analyst ratings. The company's average 12-month price target is $442.74, an increase of 6.68% from the previous average of $415.00. The high and low price targets are $500.00 and $366.00 respectively.

Portfolio Pulse from Benzinga Insights

November 07, 2023 | 4:00 pm

MLTX

Wedbush analyst Andreas Argyrides has reiterated an Outperform rating on MoonLake (NASDAQ:MLTX) and maintained a price target of $86.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 3:58 pm

DAWN

Wedbush analyst Robert Driscoll maintains an Outperform rating on Day One Biopharmaceutical (NASDAQ:DAWN) but lowers the price target from $39 to $35.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 3:55 pm

LINC

Rosenblatt analyst Steve Frankel maintains a 'Buy' rating on Lincoln Educational Services (NASDAQ:LINC) and raises the price target from $11 to $12.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 3:46 pm

PCVX

Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Vaxcyte (NASDAQ:PCVX) and maintained a price target of $58.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 3:45 pm